KRONOS BIO INC. - COM

Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology

09 Jan 2023 06:00:04 By Nasdaq GlobeNewswire

Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting

11 Dec 2022 09:00:00 By Nasdaq GlobeNewswire

Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial

07 Dec 2022 15:05:00 By Nasdaq GlobeNewswire

Kronos Bio Announces Participation in Upcoming Investor Conferences

22 Nov 2022 15:05:00 By Nasdaq GlobeNewswire

Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results

08 Nov 2022 15:10:00 By Nasdaq GlobeNewswire

Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742

08 Nov 2022 15:05:02 By Nasdaq GlobeNewswire

Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022

12 Oct 2022 03:04:45 By Nasdaq GlobeNewswire

Kronos Bio Announces Participation in H.C. Wainwright 24th Annual Global Investment Conference

06 Sep 2022 15:05:00 By Nasdaq GlobeNewswire

Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia

22 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML

16 Aug 2022 15:05:00 By Nasdaq GlobeNewswire

Kronos Bio Reports Recent Business Progress and Second-Quarter 2022 Financial Results

04 Aug 2022 15:05:02 By Nasdaq GlobeNewswire

Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress

10 Jun 2022 02:04:36 By Nasdaq GlobeNewswire

Kronos Bio Announces Participation in Upcoming Investor Conferences

01 Jun 2022 15:05:01 By Nasdaq GlobeNewswire

Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference

17 May 2022 06:00:02 By Nasdaq GlobeNewswire

Kronos Bio’s Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress

12 May 2022 09:23:18 By Nasdaq GlobeNewswire

Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results

04 May 2022 15:05:02 By Nasdaq GlobeNewswire

Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR

08 Apr 2022 12:07:03 By Nasdaq GlobeNewswire

Kronos Bio’s Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at American Association for Cancer Research Annual Meeting 2022

08 Mar 2022 16:08:22 By Nasdaq GlobeNewswire

Kronos Bio Announces Participation in Cowen 42nd Annual Health Care Conference

01 Mar 2022 06:00:02 By Nasdaq GlobeNewswire

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results

24 Feb 2022 15:05:00 By Nasdaq GlobeNewswire